Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 48 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Gill SS, Bai AD. Beta testing the potential link between the alpha antagonist tamsulosin and dementia. Pharmacoepidemiol Drug Saf 2018;27:marzo. [Ref.ID 102635]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Duan Y, Grady JJ, Albertsen PC, Wu ZH. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf 2018;27:marzo. [Ref.ID 102634]
3.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
6.Enlace a cita original
Anónimo. Manejo de la hiperplasia benigna de próstata. Infac: Información Farmacoterapéutica de la Comarca 2012;20:13-8. [Ref.ID 92706]
7.Tiene citas relacionadas Cita con resumen
Bell CM, Hatch WV, Fischer HD, Cernat G, Paterson JM, Gruneir A, Gill SS, Bronskill SE, Anderson GM, Rochon PA. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. JAMA 2009;301:1991-6. [Ref.ID 85898]
8.
Basson R, Schultz WW. Sexual dysfunction 1. Sexual sequelae of general medical disorders.. Lancet 2007;369:409-24. [Ref.ID 79074]
9.
Beach MA, Mauro LS. Pharmacologic expulsive treatment of ureteral calculi. Ann Pharmacother 2006;40:1361-8. [Ref.ID 77896]
10.
Malone M. Medications associated with weight gain. Ann Pharmacother 2005;39:2046-55. [Ref.ID 75965]
11. Cita con resumen
Anónimo. Spain introduces new reference price groups. Scrip 2004;2954:5. [Ref.ID 70164]
12.
Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350:786-99. [Ref.ID 69168]
13. Cita con resumen
Anónimo. Thiazides for uncomplicated hypertension in Norway. Scrip 2004;2923:7. [Ref.ID 69044]
14. Cita con resumen
Anónimo. Alfuzosin (Uroxatral) - another alpha1-blocker for benign prostatic hyperplasia. Med Lett Drugs Ther 2004;46:1-2. [Ref.ID 68640]
15. Cita con resumen
Anónimo. Managing lower urinary tract symptoms in men. Drug Ther Bull 2003;41:18-21. [Ref.ID 65442]
16.
Fernández Salazar L, Palencia García A. Hepatotoxicidad por terazosina. Med Clin (Barc) 2003;120:118. [Ref.ID 64947]
17. Cita con resumen
Kassabian VS. Sexual function in patients treated for benign prostatic hyperplasia. Lancet 2003;361:60-2. [Ref.ID 64738]
18. Cita con resumen
Anónimo. Dutasteride (Avodart) for benign prostatic hyperplasia. Med Lett Drugs Ther 2002;44:109-10. [Ref.ID 64552]
19. Cita con resumen
Anonymous. Countering delays in introduction of generic drugs. Lancet 2002;359:181. [Ref.ID 61019]
20.
Barry MJ, Roehrborn C G. Benign prostatic hyperplasia. BMJ 2001;323:1042-6. [Ref.ID 59391]
Seleccionar todas
 
 1 a 20 de 48 siguiente >>